Synthroid History & Development: How Levothyroxine Became the World's Most-Prescribed Drug

The 19th-Century Origins: From Myxedema to Organ Therapy

Before any pill existed, physicians in the 1880s were confronted with a disfiguring, fatal condition called myxedema. They had no name for the cause, but the clinical picture was unmistakable: weight gain, coarse skin, slowed cognition, and cardiovascular collapse in severe cases.

Murray's Sheep-Thyroid Injection (1891)

In 1891, British physician George Redmayne Murray demonstrated that subcutaneous injections of glycerin extract derived from sheep thyroid glands reversed myxedema in a 46-year-old woman. Murray GR. 1891. That patient survived 28 years on organ-extract therapy, one of the longest documented cases of continuous hormone replacement in the pre-synthetic era.

Within two years, Murray's colleagues Edward Fox and William Hector showed that oral ingestion of raw thyroid tissue produced the same reversal, meaning the active substance survived gastric digestion. This observation, published in the BMJ in 1892, set the conceptual foundation for oral thyroid replacement. Fox & Hector, BMJ 1892.

Desiccated Thyroid Extract Becomes Standard

By the early 1900s, commercially dried and powdered thyroid gland from pigs and cows (desiccated thyroid extract, or DTE) was widely manufactured. The U.S. Pharmacopeia standardized DTE by iodine content in 1905. Physicians prescribed it for decades with reasonable success, though batch-to-batch variability in T3 and T4 ratios produced unpredictable clinical responses. That variability would eventually motivate the shift to a pure synthetic compound.

Isolating and Naming Thyroxine: 1914 to 1927

Kendall's 1914 Crystallization

Edward Calvin Kendall, working at the Mayo Clinic, isolated a crystalline iodine-containing compound from thyroid glands in 1914 and named it thyroxine. Kendall EC. JAMA 1915. His extraction yielded roughly 33 grams of crystalline material from three tons of hog thyroid tissue, a yield that illustrated how potent the molecule was even at microscopic concentrations.

Kendall's thyroxine was biologically active but chemically impure by modern standards. He could not determine the full molecular structure because the analytic tools of 1914 were insufficient for a molecule as complex as an iodinated amino acid.

Harington and Barger: Total Chemical Synthesis (1927)

Charles Robert Harington and George Barger at University College London solved the structure and achieved the first total chemical synthesis of thyroxine in 1927. Harington CR, Barger G. Biochem J. 1927. Their paper confirmed thyroxine as 3,5,3',5'-tetraiodothyronine, a derivative of the amino acid tyrosine carrying four iodine atoms. This synthesis proved that a pure small molecule could replace gland-derived extracts, at least in principle.

The "L" stereoisomer (L-thyroxine, or levothyroxine) was later confirmed as the biologically active form. The D-isomer binds thyroid hormone receptors with far lower affinity and has no meaningful clinical effect at physiological doses. Mol Cell Endocrinol. 2012.

From Laboratory to Prescription: 1950s and 1960s

Commercial Synthesis Begins

Pharmaceutical manufacturers began producing synthetic L-thyroxine sodium salt in the early 1950s. Flint Laboratories (later absorbed into Abbott, and eventually AbbVie) launched Synthroid in the United States in 1955. At that point no formal NDA had been submitted to the FDA because pre-1962 drugs were exempt from the modern efficacy-and-safety review process under the Kefauver-Harris Amendment.

Synthroid entered clinical practice on the strength of animal data, small case series, and the well-established biologic activity of the thyroxine molecule itself. The drug worked. That clinical reality protected it from regulatory displacement for four decades.

Triiodothyronine (T3) Identified: Gross and Pitt-Rivers (1952)

Rosalind Pitt-Rivers and Jack Gross at the UK National Institute for Medical Research identified triiodothyronine (T3) in 1952 as a second, more potent thyroid hormone circulating at lower concentrations than T4. Gross J, Pitt-Rivers R. Lancet. 1952. This discovery complicated the clinical picture: if T3 was more active, why prescribe T4?

The answer came from peripheral deiodination research through the 1960s and 1970s, which showed that approximately 80% of circulating T3 originates from enzymatic removal of one iodine atom from T4 in liver, kidney, and muscle tissue. The thyroid itself supplies relatively little T3 directly. Levothyroxine, therefore, functions as a circulating prohormone that the body converts to its active form on demand. Bianco AC et al. Endocr Rev. 2019.

Mechanism of Action: How Levothyroxine Works at the Cellular Level

Levothyroxine works by restoring the T4 pool that the failing thyroid can no longer supply, allowing tissues to generate T3 at physiologically appropriate rates through deiodinase enzymes. The downstream effects are nuclear, not receptor-mediated at the cell membrane.

Deiodination: T4 Becomes T3

Three iodothyronine deiodinase enzymes (DIO1, DIO2, DIO3) govern the peripheral conversion of T4. DIO1 and DIO2 convert T4 to the active 3,5,3'-triiodothyronine (T3). DIO3 converts T4 to the inactive reverse T3 (rT3), acting as a metabolic brake. Bianco AC et al. Endocr Rev. 2019.

DIO2 expression is especially high in the hypothalamus and pituitary, giving those tissues a local T3 supply partly independent of serum T3. This is why TSH normalization (a pituitary readout) and peripheral tissue euthyroidism can occasionally diverge in patients on levothyroxine monotherapy, a point that informs ongoing debate about combination T4/T3 therapy.

Nuclear Thyroid Hormone Receptors (TRs)

T3 diffuses into the nucleus and binds thyroid hormone receptors TRalpha and TRbeta, both members of the nuclear receptor superfamily. Cheng SY et al. Endocr Rev. 2010. Unliganded TRs bound to thyroid hormone response elements (TREs) recruit corepressors and silence target genes. T3 binding triggers corepressor release and coactivator recruitment, switching those same genes on.

Target genes include those encoding basal metabolic rate regulators, cardiac rate and contractility proteins (particularly SERCA2a and myosin heavy chain), cholesterol synthesis enzymes (LDL receptor upregulation), and brain development factors in fetal life. This breadth explains why hypothyroidism touches nearly every organ system.

TSH as the Feedback Signal

The hypothalamic-pituitary-thyroid (HPT) axis provides the clinical monitoring framework. Low serum T4 triggers hypothalamic thyrotropin-releasing hormone (TRH) release, which stimulates pituitary TSH secretion, which drives thyroid T4 production. In primary hypothyroidism the thyroid fails; TSH rises. Exogenous levothyroxine restores T4, suppresses TSH via negative feedback, and confirms adequacy of replacement when TSH returns to the reference interval (approximately 0.4 to 4.0 mIU/L in most adults). Jonklaas J et al. Thyroid. 2014.

Regulatory History: Four Decades Without an NDA

The Pre-1962 Drug Problem

The Kefauver-Harris Amendment of 1962 required all drugs approved after that date to demonstrate efficacy through controlled trials. Synthroid, approved before 1962, was grandfathered under the Drug Efficacy Study Implementation (DESI) review process but was never formally required to file an NDA for decades. Competitors selling generic levothyroxine operated under the same regulatory gap.

By the 1990s, FDA recognized that levothyroxine had a notoriously narrow therapeutic index and that tablet potency was unstable under certain storage conditions. Stability failures led to voluntary recalls in 1997 (Synthroid among them), prompting FDA to issue a Federal Register notice in 1997 declaring that all oral levothyroxine sodium products were new drugs requiring approved NDAs. FDA Federal Register Notice, 1997.

NDA Approvals: 2000 to 2004

Abbott Laboratories (Synthroid) received FDA approval for NDA 021402 in August 2002. Several generic manufacturers followed between 2002 and 2004. The FDA approval required manufacturers to demonstrate:

• Tablet potency within 95 to 105% of labeled claim
• Stability through expiration date under ICH storage conditions
• Bioequivalence with a reference-listed drug (AUC and Cmax within 80 to 125%)

This regulatory tightening reduced the inter-lot variability that had plagued earlier decades and gave clinicians a more reliable product. FDA Drug Approval Package, NDA 021402.

Generic Bioequivalence Controversy

Whether FDA's standard bioequivalence criteria (80 to 125% AUC window) adequately protects narrow-therapeutic-index drugs like levothyroxine remains debated. The American Thyroid Association, American Association of Clinical Endocrinologists, and The Endocrine Society issued a joint statement in 2004 cautioning against automatic generic substitution without physician and patient awareness, citing case reports of TSH excursions after brand-to-generic switches. Endocr Pract. 2004. FDA subsequently tightened bioequivalence criteria for levothyroxine specifically, requiring AUC and Cmax within a tighter 90% confidence interval, narrowing permissible variability compared with standard drugs.

The ATA 2014 Guidelines: Codifying a Century of Evidence

The 2014 American Thyroid Association guidelines for hypothyroidism management by Jonklaas et al. Represent the most comprehensive synthesis of levothyroxine evidence to date. Jonklaas J et al. Thyroid. 2014. The document is 96 pages and cites over 900 references, distilling more than a century of clinical experience.

Key Recommendation: Levothyroxine Monotherapy as First-Line

The guidelines state directly: "Thyroid hormone preparations available in the United States include synthetic preparations of T4 (levothyroxine), synthetic T3 (liothyronine), synthetic combinations of T4 and T3, and desiccated thyroid... For most hypothyroid patients, the preferred therapy is levothyroxine monotherapy." The recommendation carries a Grade A level of evidence for patients with overt hypothyroidism.

Dosing Parameters From the 2014 ATA Guidelines

• Full replacement: approximately 1.6 mcg/kg/day in adults without residual thyroid function
• Start low in older patients and those with cardiac disease: 25 to 50 mcg/day, titrating every 4 to 6 weeks
• TSH target: 0.4 to 4.0 mIU/L for most adults; 0.1 to 2.5 mIU/L in the first trimester of pregnancy
• Absorption: take 30 to 60 minutes before breakfast, or consistently at bedtime (at least 3 hours after the last meal)

These parameters are reproduced in the current Synthroid prescribing information and have not changed substantively since the 2014 publication. Jonklaas J et al. Thyroid. 2014.

Absorption, Pharmacokinetics, and Drug Interactions

Levothyroxine sodium is absorbed primarily in the jejunum and ileum. Bioavailability of fasting oral tablets ranges from 60% to 80% in healthy adults. Synthroid Prescribing Information. AbbVie 2023.

The Fasting Requirement

Food reduces levothyroxine absorption by up to 40% through several mechanisms: high-fiber meals bind the drug physically, calcium in dairy products forms insoluble complexes with thyroxine, and coffee accelerates gastric motility and reduces contact time in the proximal small bowel. Benvenga S et al. Thyroid. 2008. A crossover study published in Thyroid (N=30) showed that ingesting levothyroxine with coffee raised TSH by a mean of 0.7 mIU/L compared with water-only administration.

Half-Life and Steady State

The terminal elimination half-life of levothyroxine is approximately 6 to 7 days in euthyroid adults. Steady-state serum T4 concentrations are reached after roughly five half-lives, or 4 to 5 weeks. This pharmacokinetic reality is why TSH should not be rechecked sooner than 4 to 6 weeks after any dose change. Jonklaas J et al. Thyroid. 2014.

Clinically Significant Drug Interactions

Several co-administered agents reduce levothyroxine absorption by 20 to 40%:

• Calcium carbonate supplements (separate by 4 hours)
• Ferrous sulfate (separate by 4 hours)
• Proton pump inhibitors, by reducing gastric acid needed for tablet dissolution
• Cholestyramine and colestipol (separate by 4 to 6 hours)
• Soy-based infant formulas (relevant in congenital hypothyroidism dosing)

Drugs that increase T4 clearance (phenytoin, carbamazepine, rifampin) may require dose increases of 25 to 50 mcg to maintain TSH in target range. Synthroid Prescribing Information. AbbVie 2023.

Special Populations: Pregnancy, Pediatrics, and Aging

Pregnancy

Thyroid hormone requirements increase by 25 to 50% during pregnancy because of rising TBG (thyroxine-binding globulin) levels driven by estrogen, plus placental T4 catabolism via DIO3. Stagnaro-Green A et al. Thyroid. 2011. The 2011 ATA guidelines on thyroid disease in pregnancy recommend empirically increasing the levothyroxine dose by approximately two tablets per week (roughly a 29% increase) immediately upon confirmed pregnancy, then titrating to trimester-specific TSH targets.

Untreated maternal hypothyroidism carries measurable fetal risk. A landmark study by Haddow et al. (NEJM 1999, N=62 hypothyroid mothers) found that children born to women with untreated hypothyroidism scored 7 points lower on IQ testing at age 7 to 9 compared with controls. Haddow JE et al. N Engl J Med. 1999. That single datum has shaped universal prenatal TSH screening discussions for two decades.

Congenital Hypothyroidism

Newborn screening programs identify congenital hypothyroidism at approximately 1 in 2,000 to 4,000 births. American Academy of Pediatrics. Pediatrics. 2006. Treatment with levothyroxine 10 to 15 mcg/kg/day must begin within the first 2 weeks of life to prevent permanent neurocognitive impairment. This narrow treatment window underscores the urgency of heel-stick TSH results in newborn nurseries.

Elderly Patients

TSH reference ranges shift upward with age. Adults over 80 years may have "normal" TSH values of 5 to 7 mIU/L that would indicate subclinical hypothyroidism in a 40-year-old. The TRUST trial (N=737, mean age 74.4 years) found no improvement in hypothyroid symptoms, quality of life, or fatigue scores when subclinical hypothyroidism was treated with levothyroxine versus placebo over 1 year. Stott DJ et al. N Engl J Med. 2017. That finding cautions against reflexive treatment of mild TSH elevations in older adults.

T4/T3 Combination Therapy: Where the Science Stands

A subset of patients on adequate levothyroxine monotherapy (TSH normalized) continue to report persistent fatigue, cognitive symptoms, and reduced quality of life. The prevalence of this syndrome is estimated at 10 to 15% of treated hypothyroid patients. Saravanan P et al. J Clin Endocrinol Metab. 2002.

The mechanistic hypothesis is that DIO2 genetic polymorphisms (particularly Thr92Ala-DIO2) may reduce local pituitary and brain T3 generation from T4, leaving some patients biochemically euthyroid by TSH but tissue-hypothyroid in the central nervous system. Bianco AC, Kim BW. J Clin Invest. 2006.

A practical decision framework for clinicians considering combination therapy:

1. Confirm TSH is genuinely in target range (not overtreated, not undertreated) with at least two values 6 weeks apart.
2. Exclude non-thyroidal causes of persistent symptoms: iron deficiency, sleep apnea, depression, adrenal insufficiency, celiac disease.
3. Check fT4 and fT3 simultaneously. A fT3 in the lower tertile of the reference range alongside normalized TSH may support a trial of low-dose liothyronine addition (2.5 to 5 mcg twice daily) replacing an equivalent T4 dose.
4. Reassess at 12 weeks. If no subjective improvement on blinded assessment, discontinue the T3 component.

The 2014 ATA guidelines note that "a trial of combination T4/T3 therapy might be reasonable" in patients who remain symptomatic on optimized levothyroxine, though randomized trial evidence supporting routine combination therapy remains limited. Jonklaas J et al. Thyroid. 2014.

Levothyroxine in the 21st Century: Formulation Advances

Liquid Oral Solution

Abbott/AbbVie introduced a liquid levothyroxine formulation (Tirosint-SOL in Europe; oral solution preparations approved in the U.S.) for patients with absorption problems related to achlorhydria, bariatric surgery, or interfering medications. A pharmacokinetic study (N=30) showed that liquid levothyroxine achieved AUC values approximately 22% higher than standard tablet formulation when taken with coffee, nearly eliminating the food-interaction penalty. Vita R et al. Thyroid. 2013.

Softgel Capsule (Tirosint)

Tirosint, a gelatin-encapsulated liquid formulation approved by FDA in 2010, eliminates several tablet excipients (lactose, acacia, povidone) that may affect absorption in sensitive patients. Small crossover trials suggest modestly improved T4 absorption compared with standard tablets in patients with gastrointestinal comorbidities, though the clinical significance in patients without absorption disorders is small. Cappelli C et al. Endocrine. 2013.

Prescribing Levothyroxine Today: A Practical Summary

Levothyroxine dosing is weight-based and TSH-guided. The sequence is straightforward.

Start at 1.6 mcg/kg/day for otherwise healthy adults under 60 with newly diagnosed overt hypothyroidism (TSH above 10 mIU/L). Round to the nearest commercially available tablet strength (25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200 mcg). Recheck TSH no sooner than 4 to 6 weeks after initiation or any dose change. Adjust in 12.5 to 25 mcg increments.

For subclinical hypothyroidism (TSH 4 to 10 mIU/L), treatment is indicated when: TSH exceeds 10 mIU/L, the patient has symptoms, there is a high titer of anti-TPO antibodies suggesting progression risk, or the patient is pregnant or planning pregnancy. The TRUST trial data (cited above) counsel against treatment in asymptomatic patients over 65 with mild TSH elevations. Stott DJ et al. N Engl J Med. 2017.

Monitor TSH annually once stable. Dose requirements may decrease in older adults as lean body mass falls and may increase during pregnancy, with significant weight gain, or after starting interacting drugs.